Drug Profile
Research programme: anti-inflammatory monoclonal antibodies - Kling Biotherapeutics
Latest Information Update: 20 Dec 2023
Price :
$50
*
At a glance
- Originator AIMM Therapeutics
- Developer Kling Biotherapeutics
- Class Monoclonal antibodies
- Mechanism of Action Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Autoimmune-disorders in Netherlands (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in Netherlands (Parenteral)
- 31 Dec 2012 Early research in Autoimmune disorders in Netherlands (Parenteral)